CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
CVRx (NASDAQ: CVRX) confirmed that Category I CPT codes for baroreflex activation therapy using its Barostim device replaced Category III codes effective Jan 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CVRx (NASDAQ: CVRX) confirmed that Category I CPT codes for baroreflex activation therapy using its Barostim device replaced Category III codes effective Jan 1, 2026. Category I CPT codes indicate an established procedure and can support broader adoption, coverage, and reimbursement across the U.S. healthcare system.
CVRx said U.S. hospitals and physicians should update billing systems and begin using the new codes for procedures performed on or after Jan 1, 2026. The company stated it believes the change will enable more predictable and consistent reimbursement for Barostim patients and providers.
Positive
- Category I CPT codes effective Jan 1, 2026
- Category I designation supports adoption, coverage, reimbursement
- Billing update required for procedures on or after Jan 1, 2026
Negative
- None.
Details
News Market Reaction – CVRX
On Jan 6, the day this news came out, CVRX closed 3.26% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Category I CPT effective date
- Jan. 1, 2026
- New Category I CPT codes for Barostim procedures became effective
- Shelf capacity
- $150,000,000
- Maximum amount under Form S-3 shelf registration
- Q3 2025 revenue
- $14.7M
- Quarter ended Sept. 30, 2025; up 10% year over year
- Q3 2025 gross margin
- 87%
- Improved from 83% on higher pricing and efficiencies
- Q3 2025 net loss
- $12.9M
- Quarterly net loss; $0.49 basic and diluted loss per share
- Cash & equivalents
- $85.1M
- Balance as of Sept. 30, 2025
- Long-term debt
- $50.0M
- Innovatus loan outstanding as of Sept. 30, 2025
- ATM shares issued
- 543,462 shares for $9.5M
- Shares sold via ATM during nine months ended Sept. 30, 2025
Historical Context
-
Announcement of presentation at the J.P. Morgan Healthcare Conference.
-
Participation in Piper Sandler healthcare conference fireside chat.
-
Q3 2025 revenue growth, high margins, and updated guidance.
-
Presentation plans for Jefferies Global Healthcare Conference in London.
-
Scheduling of Q3 2025 results release and conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
Category I CPT codes regulatory
Category III codes regulatory
Current Procedural Terminology (CPT) regulatory
baroreflex activation therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroreflex activation therapy using its Barostim device replaced the Category III codes as of Jan. 1, 2026. In the U.S. healthcare system, Category I CPT codes signify established procedures, supporting adoption, coverage, and reimbursement nationwide.
The new CPT codes for use with Barostim procedures are available in the reimbursement guide here, and on CVRx’s website.
U.S. hospitals and physicians performing Barostim procedures should update their billing systems and start using these new codes for all procedures performed on or after Jan. 1, 2026.
“We believe the new Category I CPT codes will enable more predictable and consistent reimbursement for Barostim patients and healthcare professionals,” said Kevin Hykes, President and Chief Executive Officer of CVRx, “and validate the important role of Barostim therapy in the heart failure treatment continuum.”
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding the anticipated effect the new codes will have on Barostim’s adoption are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about the future and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause actual results to differ from our expectations, including the actual impact the new codes have on reimbursement and patient access. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.